White House looks to CMMI to test new ways to lower drug prices
C&M Health Law
NOVEMBER 7, 2022
Phase two would have tested the use of value-based purchasing tools used by commercial health plans, hospitals and pharmacies. We expect that HHS’s response to the October 14 EO will rely upon prior issuances and statements from government officials. would disincentivize providers to prescribe higher-cost drugs.
52 
Let's personalize your content